EGFR and non-small cell lung carcinoma: Previous studies have shown that first-generation EGFR-TKIs can achieve an ORR of 62%–70% for treatment of EGFR-mutated advanced NSCLC, but radiologic remission usually occurs after 2 months of targeted therapy (Liu et al., 2022).